Aromatase inhibitors versus tamoxifen and the risk of incident intracranial meningioma: a propensity score matching analysis of 46,408 patients
Cancer Causes & Control · 2026-12 · 37 (12)
DOI: 10.1007/s10552-026-02277-3 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Causes & Control, online erschienen am 18.11.2026. Verfasst von Jeremiah Hilkiah Wijaya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, NJ, USA. jeremiah.hansum6@gmail.com. Hauptthemen laut MEDLINE: Meningioma, Tamoxifen, Aromatase Inhibitors, Breast Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Meningiomas are hormonally sensitive tumors that occur disproportionately among women with breast cancer. We compared the risk of incident meningioma among patients initiating aromatase inhibitors (AIs) versus tamoxifen.
Methods
Using the TriNetX Global Collaborative Network (181 healthcare organizations), we identified adults with breast cancer recorded during 2010–2015 who initiated anastrozole, letrozole, or exemestane versus tamoxifen, without exposure to the alternate endocrine therapy class. Cohorts were matched 1:1 on 27 covariates. Incident meningioma was assessed at 1, 2, and 3 years using risk estimates and Cox proportional hazards models.
Results
After matching, 23,204 patients were included per cohort; 23,110 AI users and 23,114 tamoxifen users without prior meningioma were included in the outcome analyses. Meningioma risk was higher with AIs at 1 year (1.51 vs 0.82 per 1,000; HR 1.846, 95% CI 1.056–3.227), 2 years (2.64 vs 1.56; HR 1.705, 95% CI 1.129–2.574), and 3 years (3.29 vs 2.29; HR 1.449, 95% CI 1.021–2.058). Absolute risk differences were 0.69, 1.08, and 1.00 per 1,000, respectively.
Conclusion
AI initiation was associated with a modestly higher but progressively attenuating relative risk of meningioma than tamoxifen, with a small absolute excess. These findings should not alter endocrine therapy selection but may inform evaluation of new dural-based lesions in AI users.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, NJ, USA. jeremiah.hansum6@gmail.com.
- School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
- Department of Neurosurgery, University of Arizona College of Medicine, Tucson, AZ, USA.
- Neurosurgical Department, Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Banten, Indonesia.
- Neurology Department, Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Banten, Indonesia.
ORCID-Profile: Jeremiah Hilkiah Wijaya
Zitieren
APA
Wijaya, J. H., Hulu, S. R. K., Lucke-Wold, B., Inggas, M. A. M., & Puspitasari, V. (2026). Aromatase inhibitors versus tamoxifen and the risk of incident intracranial meningioma: a propensity score matching analysis of 46,408 patients. Cancer Causes & Control, 37(12). https://doi.org/10.1007/s10552-026-02277-3
Vancouver
Wijaya JH, Hulu SRK, Lucke-Wold B, Inggas MAM, Puspitasari V. Aromatase inhibitors versus tamoxifen and the risk of incident intracranial meningioma: a propensity score matching analysis of 46,408 patients. Cancer Causes & Control. 2026;37(12). doi:10.1007/s10552-026-02277-3
BibTeX
@article{Wijaya2026,
author = {Wijaya, Jeremiah Hilkiah and Hulu, Soni Roy Kurniawan and Lucke-Wold, Brandon and Inggas, Made Agus Mahendra and Puspitasari, Vivien},
title = {Aromatase inhibitors versus tamoxifen and the risk of incident intracranial meningioma: a propensity score matching analysis of 46,408 patients},
journal = {Cancer Causes & Control},
year = {2026},
volume = {37},
number = {12},
doi = {10.1007/s10552-026-02277-3}
}
EUVIMED